The cost-effectiveness of aspirin for chemoprevention of colorectal cancer

References 

1. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspiring: a cost-effectiveness analysis. Gastroenterology. 2002;122:78–84
   • Abstract
   • Full Text
   • Full-Text PDF (107 KB)
   • CrossRef
2. Sonnenberg A, Delcó F, Inadomi JM. The cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med. 2000;133:573–584
   • MEDLINE
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996;
4. Bloom BB. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988;84(suppl 2A):20–24
   • Abstract
   • Full-Text PDF (476 KB)
   • CrossRef
5. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess cost from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med. 1996;11:461–469
   • MEDLINE
   • CrossRef
6. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen. Retrospective cohort study of an elderly population. Arthritis Rheum. 2000;43:917–924
   • MEDLINE
   • CrossRef
7. Wagner JL, Tunis S. Brown M, Ching A, Almeida R. The cost-effectiveness of colorectal cancer screening in average-risk adults. In:  Young G,  Levin B,  Rozen A editor. Prevention and early detection of colorectal cancer. London: Saunders; 1996;p. 321–356
8. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2044–2053
9. Hebert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med. 2000;160:3123–3127
   • MEDLINE
   • CrossRef